Immunovant (IMVT) Investor Update summary

Management and Strategic Realignment

• Eric Venker appointed CEO and Tiago Girão as CFO, with Pete Salzmann retiring and remaining as advisor; Roivant increases operational oversight and leads investor relations.

• Strategic focus on rapid clinical execution, resource allocation, and leveraging Roivant’s infrastructure for efficiency.

• Board changes include George Migausky's departure and the addition of Robert Susman and Jacob Bauer as directors.

Pipeline and Clinical Program Updates

• IMVT-1402 advanced as a potentially first- and best-in-class FcRn inhibitor across six autoimmune indications, including Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE).

• IND cleared for SjD, with a registrational trial starting summer 2025; CLE proof-of-concept study initiated with early positive data showing strong IgG reduction and clinical improvement.

• Focus narrowed to six active indications, withdrawing prior commitment to ten, to prioritize execution and value creation.

Clinical and Commercial Outlook

• Multiple pivotal and proof-of-concept studies are underway or planned, with key data readouts expected from 2026 through 2028, including Graves, MG, CIDP, SjD, and CLE.

• IMVT-1402 demonstrates robust, dose-dependent IgG lowering (~80% with 600mg weekly), favorable safety, and convenient auto-injector administration, with patent protection to 2043.

• Confident in cash runway through 2027, supporting major data milestones and potential launches.